Heat shock proteins (HSPs) have been shown to interact with antigen-presenting cells (APCs), especially dendritic cells (DCs). HSPs act as potent adjuvants, inducing a Th1 response, as well as antigen-specific CD8 1 cytotoxic T lymphocytes (CTL) via cross-presentation. Our previous work has demonstrated that Hsp70-like protein 1 (Hsp70L1), a new member of the Hsp70 subfamily, can act as a powerful Th1 adjuvant in a DC-based vaccine. Here we report the efficient induction of tumor antigen-specific T cell immune response by DCs pulsed with recombinant fusion protein of Hsp70L1 and Her2 341-456 , the latter of which is a fragment of Her2/neu (Her2) containing E75 (a HLA-A2 restricted CTL epitope). The fusion protein Hsp70L1-Her2 341-456 promotes the maturation of DCs and activates them to produce cytokines, such as IL-12 and TNF-a, and chemokines, such as MIP-1a, MIP-1b and RANTES. Taken together, these results indicate that the adjuvant activity of Hsp70L1 is maintained in the fusion protein. 
INTRODUCTION
The Th1 cellular immune response is crucial for anti-tumor and antimicrobial immunity. The administration of potent immunomodulatory adjuvants that are capable of inducing Th1 polarization is important in vaccination strategies. Heat shock proteins (HSPs), which can potently stimulate a Th1-polarized response, are prominent among these adjuvants. 1, 2 HSPs have been shown to enhance the induction of antigen-and peptide-specific cellular immunity by binding to the antigen or peptide, causing the complex to be taken up by antigen-presenting cells (APCs) and efficiently presented on major histocompatibility complex-I (MHC-I) molecules. This activity can especially be seen in dendritic cells (DCs). [1] [2] [3] [4] HSPs in these complexes, which consist of either fusion proteins complexed with antigen or peptide isolated from the tumor cells or generated artificially through covalent linkage, can interact with DCs in a receptor-mediated manner and increase MHC-II expression as well as cytokine and chemokine secretion by DCs. This interaction leads to the maturation of DCs and to their subsequent migration to draining lymph nodes, where they present antigens to T cells and initiate T-cell responses, particularly antigen-specific CD8 1 cytotoxic T lymphocyte (CTL) responses. [1] [2] [3] [4] [5] [6] Therefore, the use of HSP preparations as adjuvants, especially in DC vaccination strategies, has attracted recent attention in immunotherapy for cancer and infectious diseases.
Hsp70-like protein 1 (Hsp70L1), which is a member of the Hsp70 subfamily previously identified in our previous study, 7 has the ability to induce DC maturation and activation. Moreover, it has shown potential as a new Th1 adjuvant for use in peptide and fusion-protein immunizations for cancer treatment. 7, 8 Her2/neu (Her2), which is a member of the tumor-associated antigen (TAA) category, is a 185-kDa transmembrane glycoprotein that belongs to the family of epidermal growth-factor receptors, which contain an extracellular domain and an intracellular domain with tyrosine-specific kinase activity. 9 Her2 is overexpressed in approximately 35% of colorectal and primary renal cancers, 30% of lung adenocarcinomas, 25% of human primary breast cancers, 10% of ovarian cancers and gastric cancer, where it is correlated with the stage of cancer progression. 10 The high level of expression of Her2 in tumors makes it an attractive TAA for targeting for immunotherapeutic purposes. As a target antigen, Her2 has been extensively evaluated in both murine and human models. 11 Several immunogenic peptides derived from the Her2/neu protein that are capable of inducing peptide-specific CTLs have been reported. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] E75 (Her2 369-377 , KIFGSLAFL), a human leukocyte antigen (HLA)-A2.1-restricted CTL epitope peptide found in Her2, is the most frequently studied Her2-derived peptide in both laboratory and clinical studies. [20] [21] [22] [23] [24] [25] [26] Here, we fused Hsp70L1 with Her2 341-456 , which is a fragment of Her2 that contains the Her2-E75 epitope, to create the recombinant fusion protein Hsp70L1-Her2 341-456 . We investigated whether this fusion protein could activate DCs and whether a Her2-specific cellular response could be induced efficiently both in vitro and in vivo by DCs pulsed with this fusion protein. We demonstrated that antigenic epitopes in Her2 341-456 , when fused with Hsp70L1, were presented more efficiently as a result of the unique adjuvant effect of Hsp70L1 on DCs, and this effect consequently led to a strong induction of Her2-specific CTLs that specifically recognized and killed Her2-expressing tumor cells. These observations suggested that DCs pulsed with Hsp70L1-Her2 341-456 could represent a new therapeutic strategy for Her2-expressing cancers and further confirmed that Hsp70L1 is a potent vaccination adjuvant in cancer immunotherapy.
MATERIALS AND METHODS
Animals and cell lines HLA-A2.1/K b transgenic mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Nude mice were obtained from the Laboratory Animal Center of the Chinese Academy of Sciences (Shanghai, China). All mice were 6-to 8-week-old females and were bred and maintained under specific pathogen-free conditions. The T2 cell line (TAP-deficient, HLA-A2. 
Proteins and peptides
The Her2 341-456 cDNA sequence was synthesized and inserted into a pUC18 plasmid vector to obtain the plasmid pUC18-Her2 341-456 . The Her2 341-456 sequence used for Hsp70L1-Her2 341-456 was amplified by PCR using the pUC18-Her2 341-456 plasmid and the forward primer M13R and the reverse primer HSP-Her2-F 59-CTCTATTGAGAT-AGCATCTTGTTACGGTTTGGGTATG-39. The coding sequence of Hsp70L1 was amplified by PCR using the pPIC9k-Hsp70L1 plasmid, which contains the Hsp70L1 cDNA sequence and was constructed by our lab using the forward primer a-factor 59-TACTATTGCCAGCA-TTGCTGC-39 and the reverse primer HSP-Her2-R 59-CATACCC-AAACCGTAACAAGATGCTATCTCAATAGAG-39.
The Her2 341-456 fragment was then ligated to the C-terminus of Hsp70L1 using PCR with the forward primer a-factor and the reverse primer M13R. The pPICZa-Hsp70L1-Her2 GS115 Pichia cells were prepared according to the manufacture's instructions. The electroporating pulse was performed at 2.0 kV, 25 mF and 200 V using an Electro Cell Manipulator 600 (BTX, San Diego, CA, USA). Follow-up procedures were performed according to the manual of Pichia Expression System. The supernatants from the protein-expressing Pichia cells were collected by centrifugation at 4 uC at 10 000 g for 10 min and were analyzed for Hsp70L1-Her2 341-456 or Her2 341-456 expression using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The separated proteins were purified using phenyl-sepharose HP chromatography and SourceQ anion exchange chromatography (GE Healthcare Bio-Sciences China, Shanghai, China). The purified recombinant human Hsp70L1 protein (Hsp70L1) was obtained as described previously. 7 The purity of the recombinant Hsp70L1-Her2 341-456 fusion protein (Hsp70L1-Her2 341-456 ) and of the Her2 341-456 protein was more than 95% as indicated by silverstained sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. LPS contamination was less than 0.1 EU/mg protein as determined with the Limulus amebocyte lysate assay (BioWhittaker, Walkersville, MD, USA).
Her2-E75 and CAP-1 (CEA 605-613 , YLSGANLNL, an HLA-A2.1-restricted CTL epitope derived from CEA) peptides were synthesized at GL Biochem, Ltd (Shanghai, China) and were determined to be .95% purity using reverse phase HPLC and the purity was confirmed using mass spectrometry.
Generation of human DCs
Peripheral blood mononuclear cells were isolated from healthy donors by Ficoll/Hypaque (Sigma, St Louis, MO, USA) density gradient centrifugation. Human peripheral blood monocyte-derived DCs were generated as described previously. 27 Cytokine and chemokine production assays Human DCs were cultured for 5 days and adjusted to a final concentration of 3310 5 cells/ml in 24-well plates, after which 7.5 mg/ml of either Hsp70L1-Her2 341-456 , Hsp70L1, Her2 341-456 or phosphatebuffered saline (PBS) was added. Supernatants from designated wells were harvested after 2, 12, 24, 48 and 72 h for quantification of cytokines, such as IL-12p70 and TNF-a and chemokines, including MIP-1a, MIP-1b and RANTES using ELISA kits (R&D Systems, Minneapolis, MN, USA).
Flow cytometry analysis
After 5 days of culture, human DCs were stimulated with 7.5 mg/ml Hsp70L1-Her2 341-456 , Hsp70L1 or Her2 341-456 for 48 h. After this, the DCs were collected, washed with PBS and stained with phycoerythrin (PE)-conjugated anti-CD80, anti-CD83, anti-CD86 or fluorescein isothiocyanate-conjugated anti-HLA-DR monoclonal antibody (PharMingen, San Diego, CA, USA) for analysis using a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA, USA) and CellQuest software (Becton Dickinson).
Generation of human CTLs and isolation of CD8
1 T cells washed twice in serum-free RPMI1640 medium. 2310 6 PBLs and 2310 5 protein-pulsed autologous DCs were cocultured in 1 ml RPMI1640 medium supplemented with 10% fetal calf serum in 24-well plates. The cells were restimulated with fresh protein-pulsed autologous DCs every 7 days either two or three times. On day 3 after the second stimulation, 20 IU/ml rhIL-2 (Sigma) was added. Half of the medium was removed every 3 days and replaced with fresh medium containing rhIL-2 (20 IU/ml, cells were and expanded as necessary. On day 7 after the final stimulation, cells were harvested, and CD8
1 T lymphocytes were enriched by positive selection using immune beads (Miltenyi) following the manufacturer's recommended procedure, after which cytotoxicity was tested.
Vaccination of HLA-A2.1/K b transgenic mice HLA-A2.1/K b transgenic mice are a well-established model for studying HLA-A2.1-restricted CTL epitopes and vaccine development. 28 In this study, mouse bone marrow-derived DCs (BMDCs) were generated from HLA-A2.1/K b transgenic mice as previously described. 29 On day 5, BMDCs were harvested, plated at a cell concentration of 2310 Generation of CTLs in HLA-A2.1/K b transgenic mice 7 days after the last immunization as described above, spleens were isolated from the mice, and splenocytes were adjusted to a concentration of 2310 7 cells/well in six-well plates. The splenocytes were then stimulated with 7.5 mg/ml Her2 341-456 for 7 days in vitro. Then cells were harvested and CD8
1 cells enriched as effector cells to test the cytotoxicity to target cells.
Cytotoxicity assays
Cytotoxicity assays were performed using a standard 4-h lactate dehydrogenase (LDH) release assay. T2 cells were pulsed with 10 mg/ml Her2-E75 or CAP-1 peptide for 1 hour at 37 uC. Peptide-pulsed or non-pulsed T2 cells and Her2 1 or Her2 2 tumor cell lines were used as target cells, and were added to serial dilutions of effector cells isolated as described above in 96-well round-bottom plates at various E/T cell ratios (2.5 : 1, 5 : 1 and 10 : 1 in human CTL assays; 10 : 1, 25 : 1 and 50 : 1 in mice CTL assays). After 4 h at 37 uC, cytotoxicity was quantified by measurement of the cytosolic enzyme, LDH, in the culture supernatant using the Cyto Tox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA). Specific lysis for each E/T cell ratio is expressed as: specific lysis (%)5[(target experimental release)-(target spontaneous release)]/[(target maximum release)-(target spontaneous release)]3100%. Spontaneous LDH release in the absence of CTL was ,10% of the maximal cellular release by detergent lysis. 
Statistical analysis
The differences in the growth of SW620 tumors as measured by tumor diameters within each group were compared using the MannWhitney U test. To compare mouse survival between treatment and control groups, the Kaplan-Meier statistical analysis test was performed. All other statistical analyses were based on Student's t-test.
RESULTS
Enhanced maturation and activation of DCs treated with recombinant Hsp70L1-Her2 341-456 fusion protein Hsp70L1-Her2 341-456 and Hsp70L1 both promoted upregulation of CD80, CD83 and CD86 expression on DCs, but Her2 341-456 or PBS did not ( Figure 1 ). We observed an increase in IL-12p70 and TNF-a secretion by Hsp70L1-Her2 341-456 or Hsp70L1-stimulated DCs, but not by Her2 341-456 -or PBS-treated DCs (P,0.05) (Figure 2) . Interestingly, the production of IL-12p70 and TNF-a by Hsp70L1-Her2 341-456 -stimulated DCs was higher than that by Hsp70L1-stimulated DCs (P,0.05). The secretion levels of IL-12p70 and TNF-a reached a peak after 48 hours of DC stimulation with either Hsp70L1-Her2 341-456 or Hsp70L1. The observed cytokine profile suggested that DCs stimulated with Hsp70L1-Her2 341-456 could secrete high levels of Th1-type cytokines, such as IL-12p70, but DCs stimulated with Her2 341-456 alone could not. Human DCs produced more MIP-1a, MIP-1b , and RANTES after stimulation with Hsp70L1-Her2 341-456 than after stimulation with Her2 341-456 alone. As shown in Figure 2 , Hsp70L1-Her2 341-456 and Hsp70L1 could both induce DCs to secrete MIP-1a, MIP-1b or RANTES more than Her2 342-456 . Maximum secretion occurred after 48 h of treatment. Secretion was not detected in supernatants from either Her2 341-56 -or PBS-treated DCs (P,0.01). Additionally, the levels of MIP-1a, MIP-1b and RANTES production by DCs induced by Hsp70L1-Her2 341-456 were considerably higher than those treated with Hsp70L1, indicating that when fused with Her2 341-456 , Hsp70L1 induces greater amounts of chemokine production.
These results indicated that Hsp70L1-Her2 341-456 , like Hsp70L1, could efficiently induce phenotypic and functional maturation of DCs and activate DCs to secret increased levels of Th1-associated cytokines as well as chemokines that could recruit various kinds of immune cells contributing to initiation of an immune response. Excitingly, Hsp70L1-Her2 341-456 is more potent at inducing maturation and activation of DCs than Hsp70L1 alone. This result shows that that when Hsp70L1 is part of the Hsp70L1-Her2 341-456 fusion protein, it can act as a Th1 adjuvant, and these effects are stronger than those induced by Hsp70L1 alone.
Efficient induction of Her2-specific CD8
1 CTLs by human DCs pulsed with Hsp70L1-Her2 341-456 fusion protein We co-incubated PBLs from healthy donors and autologous DCs pulsed with Hsp70L1-Her2 341-456 or Her2 341-456 to determine whether Her2-specific CTLs could be elicited more effectively by DCs pulsed with Hsp70L1-Her2 341-456 . As shown in Figure 3 , DCs pulsed with Hsp70L1-Her2 341-456 induced the generation of Her2-specific CD8
1 CTLs in cell populations from all donors in this study, and these CTLs displayed Her2-specific killing of SW620 cells (Her2 1 , HLA-A2.1 1 ) and T2 cells pulsed with Her2-E75, but they failed to lyse SK-BR-3 cells (Her2 1 , HLA-A2.1 2 ) and CAP-1-pulsed T2 cells
(P,0.05). Lysis of non-pulsed T2 cells was not observed. The above results indicated that these CTLs were Her2-specific and HLA-A2.1-restricted. The cytotoxicity of CTLs induced by DCs pulsed with Hsp70L1-Her2 341-456 against target cells was more potent than that of CTLs induced by DCs pulsed with Her2 341-456 alone (P,0.05), further confirming the effectiveness of the adjuvant activity of Hsp70L1 in the fusion protein.
Together with the above data, our results reinforced the conclusion that the adjuvant effects of the Hsp70L1 component of the Hsp70L1-Her2 341-456 fusion protein, induced superior DC maturation and activation, and antigen bound to Hsp70L1 could be presented highly efficiently to T cells and trigger a potent Her2-specific CD8 1 T-cell response. 
Efficient induction of
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Hsp70L1-Her2 341-456 , Her2 341-456 or Hsp70L1, using PBS-treated DCs as a control. Splenocytes were isolated, stimulated and assayed for CTL cytotoxicity after three rounds of immunization in vivo. As shown in Figure 4 , splenocytes from mice immunized with DCs pulsed with Hsp70L1-Her2 341-456 or Her2 341-456 induced lysis in SW620 and Her2-E75-pulsed T2 cells, but were unable to lyse SK-BR-3 or unpulsed T2 cells. In contrast, splenocytes from mice immunized with Hsp70L1-pulsed or PBS-treated DCs showed almost no cytotoxicity toward the target cells. Splenocytes from mice immunized with DCs pulsed with Hsp70L1-Her2 341-456 showed more potent antigen-specific lysis ability toward SW620 and Her2-E75-pulsed T2 cells than those from mice immunized with DCs pulsed with Her2 341-456 (P,0.05). These observations indicated that immunization with DCs pulsed with Hsp70L1-Her2 341-456 could induce Her2-specific CTLs more efficiently in vivo and that DCs pulsed with only Hsp70L1 (without Her2) could not induce Her2-specific CTLs.
Potent anti-tumor effect of adoptive transfer of splenocytes from HLA-A2.1/K b transgenic mice immunized with DCs pulsed with Hsp70L1-Her2 341-456 fusion protein Nude mice were inoculated with SW620, a human Her2 1 /HLA-A2.1 1 carcinoma cell line. After 3 days, they were injected intravenously with in vitro Her2 341-456 -stimulated splenocytes derived from immunized HLA-A2.1/K b transgenic mice, and this was followed by intraperitoneal injections of 2000 IU IL-2 per mouse every 2 days. After three cycles of immunization, as shown in Figure 5 , adoptive transfer of splenocytes from HLA-A2.1/K b transgenic mice immunized with Hsp70L1-Her2 341-456 -pulsed DCs was able to inhibit SW620 growth in nude mice. No significant tumor growth inhibition or survival improvement was observed in other groups. All mice in the control group developed palpable tumors 4 days after tumor cell inoculation, whereas tumor growth observed in nude mice injected with splenocytes from mice immunized with Hsp70L1-Her2 341-456 -pulsed DCs was not apparent until 16 days after tumor cell injection. In this group, three of the eight mice remained tumor free, and 25% of the mice survived for longer than 90 days after SW620 tumor cell inoculation. In contrast, all mice in the control groups died between days 25 and 50 after tumor cell inoculation ( Figure 6 ). Mice receiving a low dose of IL-2 alone showed no significant difference in tumor growth when compared to the control group receiving splenocytes from HLA-A2.1/ K b transgenic mice immunized with PBS-treated DCs (data not shown). We did not observe any protection in tumor-bearing nude mice receiving splenocytes from HLA-A2. 1 Potent , in conjunction with the adjuvant activity of Hsp70L1, displayed increased immunogenicity and could be more efficiently processed and presented by DCs. More interestingly, CTLs induced by Hsp70L1-Her2 341-456 -stimulated DCs showed greater cytotoxicity towards SW620 cells than Her2-E75-pulsed T2 cells. This result suggested that vaccines based on the Her2 341-456 fragment might be immunogenic across more than one HLA type and suggests an active process of immuno-editing of Her2 341-456 antigen by DCs. Although peptide based vaccines have the disadvantage of being presented by only one HLA type, polypeptides or proteins, such as Her2 341-456 , derived from specific antigens can be presented by multiple HLA types, which could expand the vaccine coverage of patient populations.
Maturation and activation of DCs is required for the upregulation of costimulatory molecules, the enhancement of APC function and the expression of chemokine receptors, all of which promote migration to T-cell regions within the lymph node. 30 Vaccination strategies aimed at inducing immunity toward cancer or infectious diseases are strongly suggested to include the means to stimulate the maturation of the targeted DC. In this study, we found that Hsp70L1-Her2 341-456 could enhance the expression of CD80, CD83, and CD86 on DCs and promote maturation of DCs, which is critical for their APC function. 31 We observed a remarkable increase in IL-12p70 secretion by DCs stimulated with Hsp70L1-Her2 341-456 and Hsp70L1, but not by DCs treated with Her2 341-456 or PBS (P,0.05). The high levels of IL-12p70 production stimulated by Hsp70L1-Her2 341-456 or Hsp70L1 suggest that initiation of a T-cell response is important in any vaccine approach that seeks to trigger a strong anti-tumor immune response. Hsp70L1-Her2 341-456 also induced DCs to produce TNF-a, whose autocrine or paracrine secretion could stimulate DC maturation. Thus, unlike some DC-based vaccines, including protocols for maturing DCs by TNF-a or CD40 ligation, 30 Hsp70L1-Her2 341-456 may directly act on immature DCs and induce their phenotypic and functional maturation via the adjuvant activity of the Hsp70L1 portion. Moreover, in our study, MIP-1a, MIP-1b and RANTES secreted by Hsp70L1-Her2 341-456 -stimulated DCs were expected to exhibit strong chemoattractant effects on T cells, resulting in an improved immune response.
Her2 is a self-antigen with a tendency to be immunologically tolerated, which has led to the failure of several clinical immunotherapy trials. 32 Over the past few years, monoclonal antibodies targeting Her2, such as trastuzumab (Herceptin), have been approved for the treatment of patients with Her2
1 breast cancer. The significant limitation of this application is that drug resistance usually develops within 1 year from the beginning of the treatment, and a large number of patients fail to respond to treatment and relapse. 33, 34 Moreover, a risk of cardiac toxicity from Herceptin, especially in patients previously treated with anthracyclines, has been observed, which has become a therapeutic obstacle. 35, 36 DCs are now considered to be one of the best adjuvants for antitumor immunity. 31 Owing to their unique abilities to take up, process, and present antigens and to their ability to activate specific CD4 1 and CD8 1 T cells, DCs are increasingly used as vector for vaccination, and the immunogenicity of antigens delivered by DCs has now been shown in clinical settings. 31, 37, 38 The first tumor vaccine based on the usage of APCs was approved by the FDA for the treatment of patients with advanced prostate cancer. 39 The potential strength of a DC-based strategy for enhancing the immunogenicity of Her2 has been shown by the fact that Her2-expressing adenovirus transduced-DCs and Her2-E75 or other Her2-derived peptide-pulsed DC vaccines induce Her2 specific CTLs in patients with Her2 1 tumors. [40] [41] [42] In this study, the Hsp70L1-Her2 341-456 pulsed DC vaccine induced a Her2-specific CTL response and antitumor effects both in vitro and in vivo. Eventually, the potent adjuvant activity of Hsp70L1 may further reduce the weak antigenicity of Her2, and should promote the induced CTLs to kill Her2 1 tumor cells. Our observations demonstrated that this Hsp70L1-Her2 341-456 fusion protein based DC vaccine was effective for Her2 1 tumor treatment.
HLA-A2.1/K b transgenic mice expressing human HLA-A2.1 are a well-established model for studying human tumor-associated HLA-A2.1-restricted CTL epitopes and for preclinical vaccine studies. Using these transgenic mice overcomes the dual problem of human antigenic epitopes not binding to mouse MHC molecules and of mouse CD8
1 T cells not interacting with the a3 domain of human MHC molecules. 43 We investigated whether Her2-specific CTLs could be induced by immunization of HLA-A2.1/K b transgenic mice with BMDCs pulsed with Hsp70L1-Her2 341-456 . We demonstrated that the CTLs from these mice were able to lyse SW620 target cells and Her2-E75-pulsed T2 cells, showing stronger antigen-specific cytotoxicity than those generated from mice immunized with Her2 341-456 pulsed BMDCs. These results indicated the in vivo ability of BMDCs pulsed with Hsp70L1-Her2 341-456 to induce Her2-specific CTLs.
It has been well established that the adjuvant effects of HSPs in vaccination models can initiate specific cellular immune responses against associated antigens. Therefore, vaccination strategies with HSP preparations have attracted increasing attention for the immunotherapy of cancers and infectious diseases. One vaccination approach using an autologous, tumor-derived Hsp (glycoprotein 96)-peptide complex (HSPPC-96; vitespen) to treat patients at a high risk of recurrence after resection of locally advanced renal cell carcinoma has been evaluated in a phase III clinical trial. 44 As a new HSP member similar to its homologue Hsp70, Hsp70L1 has been shown to be a potent Th1 adjuvant, which could be utilized in future vaccine approaches. In our Hsp70L1-Her2 341-456 -pulsed DCs strategy, Hsp70L1 showed stronger adjuvant capabilities in the form of Hsp70L1-TAA fusion protein than Hsp70L1 alone, suggesting that Hsp70L1 could serve as an adjuvant in a fusion protein for vaccine application. Although here we examined only Her2 as an antigen, it is reasonable to predict that Hsp70L1 could be fused with a variety of other TAAs or other antigenic peptides, conferring powerful immune activating 
